Pop star Lexa reveals severe hair loss after Mounjaro use, sparks new health warnings for 2025
Pop star Lexa reveals severe hair loss after Mounjaro use, sparks new health warnings for 2025
Brazilian singer Lexa, 30, has openly shared a distressing side effect experienced after using the popular weight-loss injection Mounjaro, prompting renewed discussions about the drug’s risks. The artist disclosed that a single use of the medication led to significant hair loss, particularly along her front hairline, a revelation that underscores the individualized and sometimes unpredictable nature of such treatments. Her candid account serves as a cautionary tale for those considering or currently using GLP-1 receptor agonists for weight management.
The singer’s experience came to light in an Instagram comment this Wednesday, where she directly addressed a query from a gossip profile asking “what everyone needs to know before using Mounjaro.” Lexa’s swift response detailed her struggle, admitting that “the front of my hair fell out” following her solitary use of the injectable.
This personal setback necessitated a course of treatment to stimulate new growth, as she explained, “I had treatment to bring back the little ones in front.” Her overarching message was clear: “Mounjaro is great, but it’s not for everyone. I never took it again.”
Singer’s Experience Highlights Personal Risks
Lexa’s testimony adds a prominent voice to the growing number of individuals reporting adverse reactions to weight-loss injectables. While many users praise these medications for their effectiveness in promoting weight loss and improving self-esteem, the singer’s account highlights the less-discussed and often deeply personal side effects.
Her experience underscores that even seemingly effective treatments carry a spectrum of potential risks that vary from person to person. The decision to use such powerful medications should always be made in close consultation with healthcare professionals.
For Lexa, the drastic hair loss was significant enough to prompt immediate cessation of the drug and seek medical intervention for hair regrowth, indicating the severity of her reaction.
Broader Concerns: Anvisa’s 2025 Warnings on Injectables
Regulatory bodies continue to monitor and issue alerts regarding the use of GLP-1 receptor agonists, which include substances like tirzepatide (Mounjaro), semaglutide (Ozempic, Wegovy), dulaglutide, and liraglutide. In 2025, health authorities globally, including Brazil’s National Health Surveillance Agency (Anvisa), reinforce the critical need for professional medical supervision due to the risk of serious adverse events.
Anvisa’s ongoing surveillance indicates that serious complications, such as acute pancreatitis, remain a significant concern. This condition can progress to severe, necrotizing forms and, in some tragic cases, prove fatal. The agency has reported six deaths potentially linked to pancreatitis associated with GLP-1 agonist use in Brazil between 2020 and 2025, emphasizing the gravity of these risks.
The agency’s warnings are not new but are continuously updated to reflect the latest data and public health imperatives. Patients are strongly advised against self-medication and must adhere strictly to approved indications and medical guidance.
These alerts serve as a stark reminder that while these medications offer significant benefits for some patients, they are powerful pharmacological tools that demand careful oversight.
Understanding Mounjaro and Its Common Side Effects
Mounjaro, whose active ingredient is tirzepatide, functions by mimicking hormones that target glucose management and appetite regulation. While effective for many in managing type 2 diabetes and promoting weight loss, it is known to carry a range of common side effects beyond those Lexa experienced.
Patients using tirzepatide have reported gastrointestinal issues, with studies indicating that up to 18% of users may experience nausea, diarrhea, vomiting, or constipation. For those on semaglutide, these symptoms can affect up to 24% of users.
Other user comments and medical reports highlight additional potential adverse reactions. These include a possible decrease in the effectiveness of oral contraceptives, requiring patients to consider alternative birth control methods. While these effects are generally manageable, they contribute to the complex risk-benefit profile of these drugs.
The Critical Role of Medical Supervision
The consensus among health experts is unwavering: weight-loss injectables, including Mounjaro, must be used exclusively under strict medical prescription and continuous professional monitoring. This oversight is vital for managing potential side effects and ensuring the treatment’s appropriateness for each individual.
A thorough medical evaluation is essential to assess patient suitability, identify pre-existing conditions that might contraindicate use, and tailor dosages correctly. Regular follow-ups allow healthcare providers to monitor for adverse reactions, including less common but severe ones like pancreatitis, and to adjust treatment plans as needed.
Balancing Benefits and Risks
While stories like Lexa’s highlight significant concerns, it is also important to acknowledge the positive impacts these medications have had on many users. Reports from individuals who have successfully lost weight often cite improved self-esteem, better health markers, and an enhanced quality of life.
The journey with weight-loss medications is highly personal, and what works for one individual may pose risks for another. Open communication with healthcare providers about all potential benefits and risks remains paramount, ensuring informed decisions are made.
This ongoing dialogue between patients and doctors is critical in navigating the complexities of modern weight management treatments effectively and safely.
Lexa, Mounjaro, hair loss, weight loss drugs, GLP-1 agonists






